INNOVIVA, INC. Amortization of Intangible Assets
INNOVIVA, INC. (INVA) reported Amortization of Intangible Assets of $6.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- INNOVIVA, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $6.60M, a 1.54% increase year-over-year.
- INNOVIVA, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $6.55M, a 1.22% increase year-over-year.
- INNOVIVA, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $6.64M, a 1.94% increase year-over-year.
- INNOVIVA, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $6.60M, a 1.54% increase year-over-year.
- INNOVIVA, INC. amortization of intangible assets for fiscal 2025 was $26.28M, a 1.45% increase from fiscal 2024.
- INNOVIVA, INC. amortization of intangible assets for fiscal 2024 was $25.90M, a 18.90% increase from fiscal 2023.
- INNOVIVA, INC. amortization of intangible assets for fiscal 2023 was $21.78M, a 290.32% increase from fiscal 2022.
- INNOVIVA, INC. amortization of intangible assets for fiscal 2022 was $5.58M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.60M 10-Q · filed 2026-08-05 | $13.18M 10-Q · filed 2026-08-05 | $19.79M derived: sum of 3 quarters · filed 2026-08-05 | $26.39M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $6.55M 10-Q · filed 2026-05-06 | $13.19M derived: sum of 2 quarters · filed 2026-05-06 | $19.79M derived: sum of 3 quarters · filed 2026-05-06 | $26.29M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.24M derived: sum of 2 quarters · filed 2026-02-25 | $19.74M derived: sum of 3 quarters · filed 2026-08-05 | $26.28M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $6.60M 10-Q · filed 2025-11-05 | $13.10M derived: sum of 2 quarters · filed 2026-08-05 | $19.64M 10-Q · filed 2025-11-05 | $26.09M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $6.50M 10-Q · filed 2026-08-05 | $13.02M 10-Q · filed 2026-08-05 | $19.49M derived: sum of 3 quarters · filed 2026-08-05 | $25.99M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $6.47M 10-Q · filed 2026-05-06 | $12.99M derived: sum of 2 quarters · filed 2026-05-06 | $19.49M derived: sum of 3 quarters · filed 2026-05-06 | $25.89M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $6.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.01M derived: sum of 2 quarters · filed 2026-02-25 | $19.41M derived: sum of 3 quarters · filed 2026-02-25 | $25.90M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $6.50M 10-Q · filed 2025-11-05 | $6.51M 10-Q · filed 2024-11-06 | $12.90M derived: sum of 2 quarters · filed 2025-11-05 | $19.39M 10-Q · filed 2025-11-05 | $25.85M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $6.40M 10-Q · filed 2025-08-06 | $6.44M 10-Q · filed 2024-07-31 | $12.88M 10-Q · filed 2025-08-06 | $19.35M derived: sum of 3 quarters · filed 2026-02-25 | $25.86M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $6.44M 10-Q · filed 2025-05-07 | $12.95M derived: sum of 2 quarters · filed 2026-02-25 | $19.46M derived: sum of 3 quarters · filed 2026-02-25 | $24.42M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $6.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.02M derived: sum of 2 quarters · filed 2026-02-25 | $17.98M derived: sum of 3 quarters · filed 2026-02-25 | $21.78M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $6.51M 10-Q · filed 2024-11-06 | $11.47M derived: sum of 2 quarters · filed 2024-11-06 | $15.27M 10-Q · filed 2024-11-06 | $19.34M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $4.96M 10-Q · filed 2024-07-31 | $8.76M 10-Q · filed 2024-07-31 | $12.83M derived: sum of 3 quarters · filed 2025-02-26 | $14.34M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $3.81M 10-Q · filed 2024-05-08 | $7.88M derived: sum of 2 quarters · filed 2025-02-26 | $9.39M derived: sum of 3 quarters · filed 2025-02-26 | $9.39M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $5.58M derived: sum of 2 quarters · filed 2025-02-26 | $5.58M derived: sum of 3 quarters · filed 2025-02-26 | $5.58M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $1.51M 10-Q · filed 2023-11-01 | $1.51M derived: sum of 2 quarters · filed 2023-11-01 | $1.51M 10-Q · filed 2023-11-01 | $1.51M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | ||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 10-K/A · filed 2024-03-05 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | ||||
| 2014-09-30 | $3.23M 10-Q · filed 2014-11-04 | $5.83M derived: sum of 2 quarters · filed 2014-11-04 | $7.61M 10-Q · filed 2014-11-04 | $8.35M derived: sum of 4 quarters · filed 2014-11-04 | |
| 2014-06-30 | $2.60M 10-Q · filed 2014-08-07 | $4.38M 10-Q · filed 2014-08-07 | $5.12M derived: sum of 3 quarters · filed 2014-08-07 | $5.12M derived: sum of 4 quarters · filed 2014-11-04 | |
| 2014-03-31 | $1.78M 10-Q · filed 2014-05-07 | $2.52M derived: sum of 2 quarters · filed 2014-05-07 | $2.52M derived: sum of 3 quarters · filed 2014-11-04 | $2.52M derived: sum of 4 quarters · filed 2014-11-04 | |
| 2013-12-31 | $743.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $743.00K derived: sum of 2 quarters · filed 2014-11-04 | $743.00K derived: sum of 3 quarters · filed 2014-11-04 | $743.00K 10-K · filed 2014-03-03 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-04 | $0.00 derived: sum of 2 quarters · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 | $0.00 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-07 | ||||
| 2012-12-31 | $0.00 10-K · filed 2014-03-03 | ||||
| 2011-12-31 | $0.00 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |